Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Oncology

Anatomy, Subtypes, and Tumor Biology

At a Glance

Biliary tract and gallbladder cancers are classified by their anatomical location and genetic makeup. Tumors can occur in the gallbladder, perihilar bile ducts (Klatskin tumors), or distal bile ducts. Doctors use genetic testing to find mutations like HER2, enabling highly targeted treatments.

Understanding the anatomy and biology of your cancer is like looking at a map and a blueprint at the same time. The “map” (anatomy) tells your doctors where the tumor is and which surgical path to take, while the “blueprint” (genetics) tells them which modern medicines might work best to stop the cancer from growing [1][2].

Mapping the Anatomy: Where is the Tumor?

Biliary tract cancers are divided into subtypes based on their location. This is critical because the anatomy of the bile ducts dictates the type of surgery required [1][3].

  • Gallbladder Cancer (GBC): This starts in the gallbladder itself. Because the gallbladder sits directly against the liver, GBC can sometimes grow into the liver tissue, requiring a specialized surgical approach called a radical cholecystectomy [1][4].
  • Perihilar Cholangiocarcinoma (pCCA): Also known as a Klatskin tumor, this occurs at the “fork in the road” where the left and right hepatic ducts meet to exit the liver [1][5]. Doctors use the Bismuth-Corlette classification (Types I through IV) to describe exactly how far the tumor has traveled up into these ducts [6][7].
    • What do the types mean? Type I and II tumors are lower and generally easier to remove. Type III involves either the right or left branches higher up. Type IV involves both the right and left branches deep into the liver, making surgical removal significantly more difficult and requiring complex liver reconstruction.
  • Distal Cholangiocarcinoma (dCCA): This starts further down the bile duct, past the point where the gallbladder’s duct (the cystic duct) joins the main tube [1][5]. Because this area is very close to the pancreas, surgery for dCCA often involves the pancreas as well [8].
  • (As mentioned earlier, Intrahepatic Cholangiocarcinoma (iCCA) is another subtype that starts deep inside the liver tissue, completely separate from the extrahepatic ducts described above.)

The Blueprint: Tumor Biology and Genetics

In the past, all biliary cancers were treated the same way. Today, we use Next-Generation Sequencing (NGS) to find specific genetic mutations that act as “drivers” for the cancer [9][10].

  • HER2 (ERBB2): This mutation is particularly common in Gallbladder Cancer and some extrahepatic (perihilar and distal) cases [11][12]. If your tumor is “HER2-positive,” there are specific targeted therapies, like trastuzumab, that may be used [13][14].
  • FGFR2 Fusions & IDH1 Mutations: These genetic markers are most common in Intrahepatic Cholangiocarcinoma (iCCA), but occasionally appear in other subtypes. Drugs like pemigatinib (for FGFR2) or ivosidenib (for IDH1) are designed specifically to target these drivers [15][16][17].
  • BRAF Mutations: These are other genetic markers that help doctors personalize your care with specialized targeted treatments [18][19].

The Fuel: Chronic Inflammation

Most biliary cancers do not appear out of nowhere. Instead, they are often driven by years of chronic inflammation [20][21]. This inflammation creates a “hostile” environment that damages DNA and encourages healthy cells to turn into cancer cells over time [20].

  1. Gallstones (Cholelithiasis): In the gallbladder, the constant irritation from stones can cause chronic inflammation, which is the leading risk factor for GBC [22][20].
  2. Primary Sclerosing Cholangitis (PSC): This is a condition where the bile ducts are constantly inflamed and scarred. This persistent “biological stress” is a major driver of cholangiocarcinoma, making regular screening vital for anyone with a PSC diagnosis [23][24].
  3. DNA Damage: Over time, this inflammation can trigger early genetic mistakes, such as KRAS mutations, which set the stage for cancer to develop [25][26].

Common questions in this guide

What is a Klatskin tumor?
A Klatskin tumor, also known as perihilar cholangiocarcinoma, occurs where the left and right hepatic bile ducts meet just outside the liver. Its location determines how complex the surgical removal will be.
What does the Bismuth-Corlette classification mean?
The Bismuth-Corlette classification describes how far a perihilar cholangiocarcinoma has spread up into the bile ducts. Types I and II are lower and easier to remove, while Types III and IV involve ducts deeper in the liver and require more complex surgery.
Why is genetic testing important for gallbladder and biliary cancers?
Next-Generation Sequencing (NGS) finds specific genetic mutations, like HER2 or FGFR2, driving the tumor's growth. Identifying these markers allows doctors to use personalized, targeted therapies that work best for your specific cancer.
How do gallstones increase the risk of gallbladder cancer?
Constant irritation from gallstones causes chronic inflammation in the gallbladder. Over time, this ongoing biological stress damages DNA and creates an environment that encourages healthy cells to become cancerous.
What is the difference between perihilar and distal cholangiocarcinoma?
Perihilar cholangiocarcinoma occurs higher up in the bile ducts near the liver, while distal cholangiocarcinoma starts lower down, closer to the pancreas. The location determines which organs might need to be involved during surgery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor classified as perihilar (Klatskin) or distal, and where exactly is its 'junction' relative to my cystic duct?
  2. 2.What is my Bismuth-Corlette type, and how does that affect my surgical options?
  3. 3.Has my tumor tissue been tested for HER2 amplification, FGFR2 fusions, and BRAF mutations?
  4. 4.Given my history of chronic inflammation (like gallstones or PSC), does that change how you monitor me for recurrence or other issues?
  5. 5.Are there any clinical trials specifically for my molecular profile (e.g., HER2-positive) available at this hospital?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?

    Ricci AD, Rizzo A

    Medicina (Kaunas, Lithuania) 2021; (57(12)) doi:10.3390/medicina57121301.

    PMID: 34946246
  2. 2

    Systemic treatment options for advanced biliary tract carcinoma.

    Xie C, McGrath NA, Monge Bonilla C, Fu J

    Journal of gastroenterology 2020; (55(10)):944-957 doi:10.1007/s00535-020-01712-9.

    PMID: 32748173
  3. 3

    Robotic Klatskin Type 3A Resection with Biliary Reconstruction: Description of Surgical Technique and Outcomes of Initial Series.

    Sucandy I, Younos A, Lim-Dy A, et al.

    Annals of surgical oncology 2023; (30(13)):8559-8560 doi:10.1245/s10434-023-14256-y.

    PMID: 37684368
  4. 4

    Calcified gallbladder cancer: is it preventable?

    Thakrar R, Monib S, Pakdemirli E, Thomson S

    Journal of surgical case reports 2019; (2019(3)):rjz069 doi:10.1093/jscr/rjz069.

    PMID: 30949330
  5. 5

    Novel Targeted Therapies for Advanced Cholangiocarcinoma.

    Rizzo A, Brandi G

    Medicina (Kaunas, Lithuania) 2021; (57(3)) doi:10.3390/medicina57030212.

    PMID: 33652960
  6. 6

    Robotic Type 3B Klatskin Tumor Resection: Technique of Unification Ductoplasty for Roux-en-Y Biliary Reconstruction.

    Younos A, Ross S, Sucandy I

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2023; (27(11)):2662-2664 doi:10.1007/s11605-023-05769-8.

    PMID: 37507587
  7. 7

    [Operation treatment method of Bismuth-Corlette Ⅲ, Ⅳ hilar cholangiocarcinoma].

    Lu Z, Wang DD

    Zhonghua wai ke za zhi [Chinese journal of surgery] 2016; (54(7)):488-91 doi:10.3760/cma.j.issn.0529-5815.2016.07.003.

    PMID: 27373472
  8. 8

    Clinical Outcomes of Robotic Resection for Perihilar Cholangiocarcinoma: A First, Multicenter, Trans-Atlantic, Expert-Center, Collaborative Study.

    Sucandy I, Marques HP, Lippert T, et al.

    Annals of surgical oncology 2024; (31(1)):81-89 doi:10.1245/s10434-023-14307-4.

    PMID: 37718337
  9. 9

    Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?

    Aitcheson G, Mahipal A, John BV

    Expert opinion on investigational drugs 2021; (30(4)):463-477 doi:10.1080/13543784.2021.1900821.

    PMID: 33678096
  10. 10

    How I treat biliary tract cancer.

    Lamarca A, Edeline J, Goyal L

    ESMO open 2022; (7(1)):100378 doi:10.1016/j.esmoop.2021.100378.

    PMID: 35032765
  11. 11

    Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study.

    Lavingia V, Thummar V, Mehta P

    SAGE open medical case reports 2022; (10()):2050313X221137447 doi:10.1177/2050313X221137447.

    PMID: 36467008
  12. 12

    HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

    Galdy S, Lamarca A, McNamara MG, et al.

    Cancer metastasis reviews 2017; (36(1)):141-157 doi:10.1007/s10555-016-9645-x.

    PMID: 27981460
  13. 13

    Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma.

    Sung YN, Kim SJ, Jun SY, et al.

    Frontiers in oncology 2021; (11()):658564 doi:10.3389/fonc.2021.658564.

    PMID: 34367955
  14. 14

    Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient.

    Wang L, Li X, Cheng Y, et al.

    Frontiers in immunology 2021; (12()):784861 doi:10.3389/fimmu.2021.784861.

    PMID: 35069555
  15. 15

    Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis.

    Niu S, Zhang Y, Li Z, Wang T

    Liver international : official journal of the International Association for the Study of the Liver 2024; (44(9)):2208-2219 doi:10.1111/liv.15984.

    PMID: 38829010
  16. 16

    Current challenges to underpinning the genetic basis for cholangiocarcinoma.

    Cigliano A, Chen X, Calvisi DF

    Expert review of gastroenterology & hepatology 2021; (15(5)):511-526 doi:10.1080/17474124.2021.1915128.

    PMID: 33888034
  17. 17

    Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer.

    Leowattana W, Leowattana T, Leowattana P

    World journal of gastrointestinal oncology 2023; (15(6)):959-972 doi:10.4251/wjgo.v15.i6.959.

    PMID: 37389105
  18. 18

    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

    Abou-Alfa GK, Sahai V, Hollebecque A, et al.

    The Lancet. Oncology 2020; (21(5)):671-684 doi:10.1016/S1470-2045(20)30109-1.

    PMID: 32203698
  19. 19

    Chinese expert consensus on the clinical application of molecular diagnostics in hepatobiliary cancers (2024 edition).

    Ainiwaer A, Cheng J, Lang R, et al.

    Liver research 2024; (8(4)):195-206 doi:10.1016/j.livres.2024.11.005.

    PMID: 39958921
  20. 20

    Biliary tract cancer.

    Valle JW, Kelley RK, Nervi B, et al.

    Lancet (London, England) 2021; (397(10272)):428-444 doi:10.1016/S0140-6736(21)00153-7.

    PMID: 33516341
  21. 21

    Expression of the large amino acid transporter SLC7A5/LAT1 on immune cells is enhanced in primary sclerosing cholangitis-associated cholangiocarcinoma and correlates with poor prognosis in cholangiocarcinoma.

    Branchi V, Hosni R, Kiwitz L, et al.

    Human pathology 2024; (153()):105670 doi:10.1016/j.humpath.2024.105670.

    PMID: 39406289
  22. 22

    Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.

    Sturm N, Schuhbaur JS, Hüttner F, et al.

    Cancers 2022; (14(22)) doi:10.3390/cancers14225580.

    PMID: 36428670
  23. 23

    Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.

    Catanzaro E, Gringeri E, Burra P, Gambato M

    Cancers 2023; (15(20)) doi:10.3390/cancers15204947.

    PMID: 37894314
  24. 24

    Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis.

    Lee JJ, Schindera ST, Jang HJ, et al.

    Abdominal radiology (New York) 2017; (42(12)):2898-2908 doi:10.1007/s00261-017-1328-8.

    PMID: 28951947
  25. 25

    Pixel-Level Clustering of Hematoxylin-Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer.

    Inoue H, Aimono E, Kasuga A, et al.

    Biomedicines 2022; (10(12)) doi:10.3390/biomedicines10123133.

    PMID: 36551889
  26. 26

    Genomic mutation characteristics and prognosis of biliary tract cancer.

    Guo L, Zhou F, Liu H, et al.

    American journal of translational research 2022; (14(7)):4990-5002.

    PMID: 35958441

This page provides educational information about biliary and gallbladder cancer anatomy and genetics. Always consult your oncologist or surgical team to understand the specific details of your diagnosis and treatment plan.

Get notified when new evidence is published on Carcinoma of gallbladder and extrahepatic biliary tract.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.